Ginkgo Bioworks Holdings (DNA) is up 24% in after-hours trading

[appman]

Ginkgo Bioworks Holdings (NYSE:DNA) is up 24% in after-hours trading after releasing Q2 2022 results that included a boost in its full-year revenue outlook.
The cell programming platform company now projects 2022 revenue of $425M-440M, up from a previous of $375M–390M. The consensus estimate is $384.5M.
The quarterly net loss of $670.6M compares to $54.9M in Q2 2021, which was a miss.
Ginkgo Bioworks (DNA) was significantly impacted in the quarter by a 664% increase in total operating expenses to $791.5M compared to the prior-year period, which was a miss.
Revenue of ~$144.6M, a ~231.4% year-over-year increase, however, was a beat.
The company ended the quarter with ~$1.4B in cash and cash equivalents, compared to ~$1.6B at Dec. 31, 2022.
Check out Seeking Alpha contributor Real Investments' bullish argument for Ginkgo Bioworks (DNA).